AiTan (rivoceranib) / Jiangsu Hengrui Pharma, HLB Bio Group, Bukwang Pharma, Advenchen - LARVOL DELTA

Case Report: Durable complete response of advanced-stage hepatocellular carcinoma to DEB-TACE combined with lenvatinib and camrelizumab. (PubMed, Front Immunol) - "Initially, he received apatinib in combination with camrelizumab; however, due to intolerance to apatinib's side effects, the regimen was adjusted to lenvatinib and camrelizumab. The combination of DEB-TACE, lenvatinib, and camrelizumab demonstrated efficacy in a patient with advanced HCC and lung metastases. These findings suggest that integrating MKIs and ICIs may represent a potential treatment approach for select advanced HCC cases, warranting further validation in larger studies."

Journal • Fibrosis • Gastroenterology • Hepatitis B • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Liver Cirrhosis • Oncology • Solid Tumor

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=25 | Terminated | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | N=230 ➔ 25 | Unknown status ➔ Terminated; The sponsor's R&D strategy is adjusted.

Enrollment change • IO biomarker • Trial termination • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS

Cholesterol confers resistance to Apatinib-mediated ferroptosis in gastric cancer. (PubMed, Cell Biosci) - No abstract available

Journal • Gastric Cancer • Oncology • Solid Tumor

Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping: Chemotherapy, Immunotherapy, or Targeted Therapy?-A Retrospective Analysis. (PubMed, Ann Surg Oncol) - "Our analysis has revealed that, for neoadjuvant therapy in AGC, the mesenchymal subtype stands out as the ideal patient population benefiting from Apatinib."

IO biomarker • Journal • Retrospective data • Gastric Cancer • Oncology • Solid Tumor

Research letter: immune checkpoint inhibitors against thyroid cancer. (PubMed, Int J Surg) - "The study presents some valuable insights regarding the present state and future perspectives of clinical trials on thyroid cancer."

Checkpoint inhibition • IO biomarker • Journal • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • BRAF

Conversion therapy with sintilimab combined with chemotherapy and apatinib in stage IV gastric cancer. (PubMed, Int J Cancer) - "We explored the feasibility and efficacy of sintilimab plus two-drug chemotherapy (S-1 plus nab-paclitaxel) and apatinib as conversion therapy in patients with stage IV gastric cancer in China...The safety profile was manageable. Sintilimab plus chemotherapy and apatinib followed by conversional resection may be a new feasible and safe option for initially unresectable gastric cancer, potentially leading to long-term survival or even cure."

Journal • Gastric Cancer • Oncology • Solid Tumor

ICT-HCC: Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - P=N/A | N=300 | Recruiting | Sponsor: Nanjing Tianyinshan Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • IO biomarker • Hepatocellular Cancer • Oncology • Solid Tumor

Phase II study of transcatheter arterial chemoembolization (TACE) combined with apatinib for advanced perihilar cholangiocarcinoma. (PubMed, Sci Rep) - "A comprehensive treatment plan involving TACE combined with targeted therapy was implemented for the patients with pathologically diagnosed advanced PCC, where TACE was performed every 4-6 weeks to deliver albumin paclitaxel and gemcitabine for a maximum of six times. Among the most common AEs were bone marrow suppression and hand-foot syndrome, while no patient had Grade 4 AE. Comprehensive treatment combining TACE with apatinib for advanced PCC had favorable therapeutic effects, and no major safety issue was observed in the patients enrolled."

Journal • P2 data • Biliary Cancer • Cholangiocarcinoma • Dermatology • Oncology • Solid Tumor

Association of alpha-fetoprotein (AFP) and clinical outcomes in patients with unresectable hepatocellular carcinoma (uHCC) treated with camrelizumab + rivoceranib vs sorafenib (CARES-310) (ESMO-GI 2025) - P3 | "These results suggest meaningful clinical benefit of cam + rivo as first-line therapy for uHCC compared to sor regardless of baseline AFP level or etiology."

Clinical • Clinical data • Hepatocellular Cancer • Oncology • Solid Tumor • AFP • FLT1

MAPPING THE DIVERSITY OF IMMUNOTHERAPY IN TRIPLE NEGATIVE BREAST CANCER: TREATMENTS, OUTCOMES, AND SIDE-EFFECTS WITH IMMUNE CHECKPOINT INHIBITORS (MASCC-ISOO 2025) - "Results Treatments included monotherapies with PD-1 inhibitors (e.g., Pembrolizumab, Nivolumab), PD-L1 inhibitors (e.g., Atezolizumab, Durvalumab), and combination therapies with chemotherapy (e.g., Nab-paclitaxel, carboplatin), targeted therapies (e.g., Apatinib, Olaparib), and radiotherapy (e.g., stereotactic body radiotherapy). While immune-related AEs were common, they were largely manageable. Further research into novel combinations and biomarker validation is essential to advance precision immunotherapy for TNBC."

Adverse events • Checkpoint inhibition • IO biomarker • Tumor mutational burden • Breast Cancer • Fatigue • Neutropenia • Oncology • Solid Tumor • Triple Negative Breast Cancer • CD8 • TMB

The evaluation of the efficacy and safety about apatinib combined with immune checkpoint inhibitors in advanced gastric cancer: a real-world study. (PubMed, Front Oncol) - "Safety profiles were comparable between groups, with no significant increase in severe adverse events with combination therapy. Apatinib combined with ICIs demonstrated improved survival outcomes compared to apatinib monotherapy in AGC, particularly for patients with liver metastasis, without increasing severe toxicity."

Checkpoint inhibition • Journal • Real-world evidence • Gastric Cancer • Oncology • Solid Tumor

CAMRELIZUMAB PLUS LOW-DOSE APATINIB AND PEGASPARGASE FOLLOWED BY RADIOTHERAPY FOR NEWLY DIAGNOSED STAGE I/II NATURAL KILLER/T-CELL LYMPHOMA: A MULTICENTER PHASE II STudy (ICML 2025) - "The combination of camrelizumab, low-dose apatinib, and pegaspargase followed by radiotherapy demonstrated significant efficacy and manageable toxicity in newly diagnosed stage I/II NK/TCL. The promising CR rates and favorable safety profile suggest that this regimen could serve as a viable alternative to conventional chemoradiotherapy for this patient population."

Clinical • P2 data • Hematological Malignancies • Lymphoma • Natural Killer/T-cell Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

Hepatic Arterial Infusion Chemotherapy Combined Apatinib/Camrelizumab for Recurrent Hepatocellular Carcinoma After Hepatectomy. (PubMed, J Hepatocell Carcinoma) - "All adverse events were manageable, and no treatment-related deaths occurred. HAIC combined with apatinib/camrelizumab is effective and safe in the treatment of recurrent HCC after hepatectomy, which may be a promising treatment for recurrent HCC."

Journal • Hepatocellular Cancer • Oncology • Solid Tumor

Neoadjuvant Treatment of Ovarian Cancer With Fluazoparib in Combination With Apatinib (clinicaltrials.gov) - P2 | N=48 | Not yet recruiting | Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

New P2 trial • Oncology • Ovarian Cancer • Solid Tumor

Significance of hemoglobin and hematocrit changes in predicting patient survival and efficacy of neoadjuvant chemotherapy for advanced gastric cancer. (PubMed, World J Gastrointest Oncol) - "Hematocrit < 33% and hemoglobin < 107 g/L are risk factors for chemotherapy failure in patients with advanced gastric cancer. They are associated with poorer prognosis and reduced 3-year survival rates."

Journal • Gastric Cancer • Hematological Disorders • Oncology • Solid Tumor

A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=43 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Xiamen University

New P2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Case report of complete remission in two patients with Barcelona stage C hepatocellular carcinoma treated with apatinib combined with camrelizumab. (PubMed, Am J Transl Res) - "This report presents two cases of Barcelona Clinic Liver Cancer (BCLC) stage C HCC that achieved complete remission following treatment with apatinib plus camrelizumab. According to the Response Evaluation Criteria in Solid Tumors, both patients achieved complete response, allowing for drug discontinuation."

Journal • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: Ruijin Hospital

New P2 trial • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

BCMA/GPRC5D BISPECIFIC CAR T-CELL THERAPY FOLLOWING APATINIB BRIDGING TREATMENT IN RELAPSED/REFRACTORY MULTIPLE MYELOMA WITH EXTRAMEDULLARY DISEASE: A SINGLE-ARM, SINGLE-CENTER PHASE 1 TRIAL (EHA 2025) - "This Phase I trial suggests that apatinib bridging therapy followed by anti-BCMA/GPRC5D bispecific CAR T-cell therapy is a feasible, safe, and effective approach for relapsed/refractory multiple myeloma with extramedullary disease. Long-term safety and efficacy need further investigation. Larger controlled trials are needed to confirm these findings and refine treatment protocols."

CAR T-Cell Therapy • Clinical • P1 data • Hematological Disorders • Hematological Malignancies • Hepatology • Liver Failure • Multiple Myeloma • Oncology

AMBITION: Neoadjuvant Therapy for Locally Advanced Colon Cancer (clinicaltrials.gov) - P2 | N=64 | Completed | Sponsor: Zhejiang University | Recruiting ➔ Completed

Trial completion • Colon Cancer • Colorectal Cancer • Oncology • Solid Tumor

Clinical Efficacy and Safety of Apatinib Combined with Irinotecan in HER2-negative Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma after First-Line Treatment Failure: A Single-Arm, Single-Center Retrospective Study. (PubMed, J Gastrointest Cancer) - "Apatinib combined with irinotecan demonstrates modest efficacy with manageable safety profiles in HER2-negative patients with advanced gastric or GEJ adenocarcinoma for whom first-line treatment has failed. Further prospective studies are warranted."

Journal • Retrospective data • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • HER-2

JAK3/STAT5A-dependent IL-8 regulation drives ESCC angiogenesis and is suppressed by dihydroartemisinin. (PubMed, Int Immunopharmacol) - "Notably, dihydroartemisinin (DHA) directly targeted JAK3 and inhibited ESCC CM-induced HUVECs angiogenesis and the ESCC angiogenesis in vivo, similar to the clinical drugs Avastin or Apatinib. Besides, DHA inhibited ESCC angiogenesis through JAK3/STAT5A/IL-8 signaling in vivo and in vitro, and JAK3 blockade alleviated its effect. In conclusion, these findings demonstrate a critical role of the JAK3/STAT5A/IL-8 pathway in regulating ESCC angiogenesis, and DHA is an effective drug for targeting JAK3 against ESCC angiogenesis, providing a research basis and a new strategy for anti-ESCC angiogenesis therapy."

Journal • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma • CXCL8 • JAK3 • STAT5 • STAT5AWqe

Continuation of serplulimab-based therapy beyond first progression in advanced gastric/gastroesophageal junction (G/GEJ) cancer: Preliminary results from the SCAFIGC trial. (ASCO 2025) - P2 | "All patients received 6-8 cycles of serplulimab combined with XELOX (oxaliplatin and capecitabine), followed by maintenance serplulimab plus capecitabine until disease progression, intolerable toxicity, or death...These patients were randomized (2:1) to receive serplulimab combined with apatinib and paclitaxel or paclitaxel ± ramucirumab... Patients with advanced G/GEJ cancer demonstrate promising clinical efficacy and manageable safety after receiving first-line serplulimab combined with chemotherapy. Further follow-up is needed to assess the potential for long-term benefit and to evaluate the efficacy and safety of the stage II treatment."

Metastases • Gastric Cancer • Oncology • HER-2 • PD-L1

Proteomics profiling reveals the potential targets of Apatinib inhibiting the proliferation of glioma U251 cell. (PubMed, Biochem Biophys Res Commun) - "Molecular docking studies further substantiated our findings, showing strong binding affinity between Apatinib and both DKK1 and PARP14. Collectively, our results suggest that these proteins represent promising therapeutic targets for glioma treatment."

Journal • Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor • DKK1 • PARP1

The appropriate therapeutic sequence with angiogenesis inhibitor and chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Exploratory analysis from the phase 3 FRUTIGA study. (ASCO 2025) - P3 | "In China, approved AI-based treatments include ramucirumab (a monoclonal antibody AI targeting VEGFR-2) plus paclitaxel (PTX) for 2L therapy, and apatinib (a small-molecule AI targeting VEGFR-2) for 3L therapy... In the FRUTIGA study, eligible patients (pts) were randomized to receive fruquintinib (F, an AI targeting VEGFR-1/2/3) or placebo (PBO) + PTX for 2L therapy...The commonly used C in FP-C arm were irinotecan (70.7%) and PTX (17.2%); the most commonly used AI in PP-AI arm was apatinib (93.2%)... This analysis revealed superior survival benefits in FP-C arm vs PP-AI arm, which indicates that compared with chemotherapy followed by angiogenesis inhibitor-based therapy, the therapeutic sequence of angiogenesis inhibitor-based therapy followed by chemotherapy may be predictive of better clinical outcomes for pts with advanced gastric or gastroesophageal junction adenocarcinoma. However, this exploratory analysis warrants further study."

Clinical • Metastases • P3 data • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • FLT1 • KDR